HuGE Literature Finder
Records 1-3
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Apr 22 (4): 890-6. Park S R, Kong S-Y, Rhee J, Park Y-I, Ryu K W, Lee J H, Kim Y-W, Choi I J, Kim C G, Lee J Y, Cho S-J, Kim N |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Feb 11 (3): 1226-36. Carlini Leslie E, Meropol Neal J, Bever John, Andria Michael L, Hill Todd, Gold Philip, Rogatko Andre, Wang Hao, Blanchard Rebecca |
Pharmacogenetic analysis of UGT1A1, UGT1A6, UGT1A7 and thymidylate synthase in a phase II study of capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jul 22 (14_suppl): 3623. Carlini L E, Meropol N J, Chen Y-M, McGarry C, Hill T, Gold P, Blanchard R |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 15, 2021
- Content source: